We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.25 | 1.10 | 1.40 | 1.25 | 1.25 | 1.25 | 592,472 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 597k | -477k | -0.0035 | -3.57 | 1.69M |
Date | Subject | Author | Discuss |
---|---|---|---|
08/5/2018 21:55 | As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the fastest-growing development programs in the industry evaluating oncology medicines in more than 30 tumor types. | myamay16 | |
08/5/2018 21:51 | PYC- is not a cancer research company. It is a systems biology company that models cancer cell activity etc. it it tries to simulate cancer cell growth etc etc and how drugs can best target it. It is a simulation company not involved in canser research directly!! | smcl | |
08/5/2018 21:47 | Myanmay16- relevance to systems biology??? | smcl | |
08/5/2018 21:28 | Merck’s Focus on Cancer Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck, helping people fight cancer is our passion and supporting accessibility to our cancer medicines is our commitment. Our focus is on pursuing research in oncology and we are accelerating every step in the journey – from lab to clinic – to potentially bring new hope to people with cancer. As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the fastest-growing development programs in the industry evaluating oncology medicines in more than 30 tumor types. We also continue to strengthen our oncology portfolio through strategic acquisitions and are prioritizing the development of several promising candidates with the potential to improve the treatment of advanced cancers. For more information about our oncology clinical trials, visit www.merck.com/clinic Liked this part. As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the fastest-growing development programs in the industry evaluating oncology medicines in more than 30 tumor types. | myamay16 | |
08/5/2018 18:57 | STUG/STUCK- he’s small potatoes. | smcl | |
08/5/2018 18:08 | Hope so mate, don't forget us when you get there ;) | margic | |
08/5/2018 17:47 | All I know is that my company spacedust mining will be a multi billion company | spacedust | |
08/5/2018 17:46 | Coz there would need to be a rns | spacedust | |
08/5/2018 17:14 | He has 2.75 percent more debt than I do. If you believe it, wonder why he won't go over 3 percent... | davevt | |
08/5/2018 16:48 | Dave- he’s nervous. I would be with 2.75% nearly 200k riding on a small tiddler! | smcl | |
08/5/2018 16:29 | Daves butt must still be sore considering he still remembers the poster he was engaging with | hms_trader | |
08/5/2018 15:21 | Yes exactly 'stop making out you have people's best interests at heart', he was a total b.s deramper who never got what he wanted. Just like the rampers. Anyway, how's your 2.75 percent doing today Jack?.... | davevt | |
08/5/2018 12:11 | derampers who lie, exactly. And hence why the price never went to where they said it would. Much like rampers who lie, and the price doesn't go to where they said it will. Both are my targets. | davevt | |
08/5/2018 10:19 | Yeah check it out, I argue with both sides of the coin if neither can back up what they are saying with evidence, rampers and derampers. | davevt | |
08/5/2018 09:31 | Daveavt was bum raped by derampers on MAFL and has been traumatised ever since, doing what was inflicted on him to other shares. Poor thing. See for yourselves on the MAFL LSE boards from H2 last year. | hms_trader | |
08/5/2018 08:39 | The market is the one that believes it's valueless, hence the price. I'm just here putting to task anyone that wildly claims otherwise, because they can't back it up. Everything has 'value', at the right price. Share 'prices' are are irrelevant, all that matters is the difference of what you buy and sell at. But people on here are trying to convince themselves that a 5 quid note is actually worth 20. No, it's worth 5. But why aren't you happy with a 5 quid note being worth 5 quid? Because someone convinced you it was worth 10 and you fell for it.. | davevt | |
08/5/2018 08:03 | FARN today follows IMM with a major Phase III failure. When will investors realise that in a gold rush it's better to buy the providers of picks and shovels? In the biotech/Pharma world that should mean favouring the likes of PYC | the stigologist | |
08/5/2018 02:20 | Smcl and Daveavt and nothing but derampers trying to dominate these boards with negativity for their own selfish ends. This Dave character is particularly unsavoury having moved to posting his drivel on advfn whereas previously it was just confined to LSE. Obviously desperate to deramping this, why else would someone care so much for a stock they believed was valueless | hms_trader | |
07/5/2018 20:36 | All I know is that I could be a billionaire because the giants in my industry are. I'm digging with a spatula | spacedust | |
07/5/2018 11:40 | What is your problem smcl? Simply responding to every post stig makes with a negative post with ZERO facts in it shows you to be a massive wazzock. Try putting the counter argument so people can make an informed decision otherwise it's you who is the deramper and stig is the reasoned investor. | coldspring | |
07/5/2018 11:36 | In the opinion of the Great STUG/Stuck | smcl |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions